Evauation of usefulness of clopidogrel bisulfate against ischemic cerebrovascular disorders

Evauation of usefulness of clopidogrel bisulfate against ischemic cerebrovascular disorders - DuaLS study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000006870

Enrollment

Registered

2011-12-12

Start date

2011-12-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lacunar stroke

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients with written informed consent 2.Patients with ischemic cerebrovascular disease (1)Supratentorial lacunar infarction (2)Infarction radiologically diagnosed with MRI or CT 3.Patients who can receive antiplatelet agents orally or with tube feeding

Exclusion criteria

Exclusion criteria: 1) Patients involved in other interventional study/trials 2) Patients treated with cancer, infarction, or febrile disease 3) Patients with atherothrombotic infarction or cardiogenic embolism 4) Patients who have contraindications to clopidogrel written in a package leaflet 5) Patients who have already received clopidogrel 6) Patients who have already received two types of antiplatelet agents or anticoagulants 7) Patients who have already received t-PA 8) Patients who had surgery within 30 days

Design outcomes

Primary

Measure	Time frame
mRS score at 90 days	—

Secondary

Measure	Time frame
Cardiovascular event Hemorrhagic compication Other functional outcome	—

Countries

Japan

Outcome results